India’s Central Drugs Standard Control Organisation (CDSCO) is moving to implement new regulations aimed at preventing the use of brand name extensions for drugs that are not related to the original product. This initiative seeks to standardize drug nomenclature and mitigate potential confusion among consumers and healthcare professionals.
In a parallel development impacting business operations and legal standing, India’s High Court has issued a ruling that prevents sole traders from utilizing the ‘company name exception’ to evade regulatory requirements or liabilities. The judgment emphasizes a clear distinction between individual business entities and formally incorporated companies, affecting how sole proprietors can leverage company names in their operations.
About the Author
